Lv2
158 积分 2024-12-04 加入
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
11天前
已完结
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer
11天前
已完结
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy
11天前
已完结
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
1个月前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
1个月前
已完结
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
2个月前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2个月前
已完结
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
2个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
3个月前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
3个月前
已完结
皖公网安备34019202002308
